Shantou University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Shantou China (1981)

Organization Overview

First Clinical Trial
2006
NCT00744302
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Cancer Hospital of Shantou University | Cancer Hospital, Shantou University Medical College | Department of Nephrology, People's Hospital Guangdong Provincial | Department of nephrology, People's Hospital of Guangdong Province | First Affiliated Hospital of Shantou University Medical College | First Affiliated Hospital of Shantou University Medical Collegeity | Guangdong Cardiovascular Insititution, Guangdong General Hospital, Guangdong Academy of Medical Science | Guangdong Cardiovascular Institute,Guangdong General Hospital | Guangdong General Hospita | Guangdong General Hospital | Guangdong General Hospital (GGH)& Guangdong Academy of Medical Sciences | Guangdong General Hospital, Guangdong, 510030, China | Guangdong General Hospital & Guangdong Academy of Medical Sciences | Guangdong General Hospital, Guangdong Academy of Medical Sciences | Guangdong General Hospital&Guangdong Academy of Medical Sciences | Guangdong Province People's Hospital | Guangdong Provincial People's Hospital | Jiyan Chen | Longgang District Central Hospital of Shenzhen | Nephrology Dept,Guangdong General Hospital | Nephrology Dept.,Guangdong General Hospital | No. 106 Zhongshan er Road, Guangzhou, Guangdong | People's Hospital Guangdong Provincial | People's Hospital of Guangdong Province | Shantou Central Hospital | Shantou University Medical College | The Second Affiliated Hospital of Shantou University Medical College

Active Ingredients

Drugs in Phase 4 Trials (54)

acetylsalicylic acid (aspirin) (3 trials)

adefovir dipivoxil (hepsera) (1 trial)

allisartan isoproxil (2 trials)

amiloride (midamor) (1 trial)

amiodarone (cordarone) (1 trial)

amlodipine (norvasc) (3 trials)

amoxicillin (1 trial)

beinaglutide (1 trial)

berberine (1 trial)

bismuth (1 trial)

cenegermin-bkbj (oxervate) (1 trial)

clarithromycin (biaxin) (1 trial)

cyclophosphamide (cytoxan) (8 trials)

cytarabine (cytosar-u) (2 trials)

dexamethasone (2 trials)

digoxin (lanoxin) (1 trial)

dulaglutide (trulicity) (1 trial)

entecavir (baraclude) (1 trial)

esomeprazole (nexium) (1 trial)

flumatinib (1 trial)

fluvoxamine (luvox) (1 trial)

gliclazide (1 trial)

hydrochlorothiazide (esidrix) (2 trials)

ibandronate (boniva) (1 trial)

idarubicin (idamycin) (2 trials)

insulin glargine (toujeo) (2 trials)

insulin human (humulin) (2 trials)

interferon alpha-2b (Intron-A) (1 trial)

iodixanol (visipaque) (1 trial)

iopamidol (Isovue) (1 trial)

itraconazole (sporanox) (1 trial)

linagliptin (tradjenta) (1 trial)

mercaptopurine (purinethol) (1 trial)

methylphenidate (ritalin) (1 trial)

mycophenolate (CellCept) (2 trials)

naltrexone (revia) (3 trials)

prednisone (meticorten) (4 trials)

probucol (lorelco) (2 trials)

propofol (diprivan) (2 trials)

remifentanil (ultiva) (1 trial)

rifampin (1 trial)

rivaroxaban (xarelto) (1 trial)

sevoflurane (ultane) (1 trial)

sitagliptin (januvia) (1 trial)

sorafenib (nexavar) (3 trials)

tacrolimus (prograf) (3 trials)

telbivudine (tyzeka) (1 trial)

thalidomide (Thalomid) (1 trial)

thrombopoietin (3 trials)

thymalfasin (zadaxin) (1 trial)

urea (2 trials)

valsartan (diovan) (3 trials)

vincristine (oncovin) (2 trials)

vonoprazan (Voquezna) (1 trial)

Drugs in Phase 3 Trials (63)

131i-lipiodol (Lipiodol) (3 trials)

abivertinib (1 trial)

alemtuzumab (campath) (1 trial)

allogeneic blood cells (2 trials)

allopurinol (zyloprim) (1 trial)

aprepitant (Emend) (1 trial)

arsenic trioxide (trisenox) (1 trial)

autologous mesenchymal stem cells (8 trials)

azathioprine (imuran) (1 trial)

azd3759 (2 trials)

bevacizumab (avastin) (1 trial)

camrelizumab (3 trials)

capecitabine (xeloda) (7 trials)

carboplatin (paraplatin) (18 trials)

cd25 monoclonal antibody (1 trial)

cisplatin (platinol) (18 trials)

cladribine (leustatin) (1 trial)

clopidogrel (plavix) (1 trial)

cs1001 (1 trial)

danshen (1 trial)

docetaxel (taxotere) (7 trials)

dydrogesterone (gynorest) (1 trial)

enarodustat (1 trial)

epirubicin (ellence) (5 trials)

erlotinib (tarceva) (10 trials)

febuxostat (uloric) (1 trial)

Filgrastim (neupogen) (1 trial)

fluorouracil (efudex) (8 trials)

fulvestrant (faslodex) (1 trial)

gefitinib (iressa) (6 trials)

gelatin (2 trials)

gemcitabine (gemzar) (9 trials)

glucose (1 trial)

hyaluronic acid (1 trial)

icotinib (Conmana) (1 trial)

lenvatinib (lenvima) (2 trials)

letrozole (femara) (2 trials)

leucovorin (1 trial)

megakaryocytic progenitor cells (1 trial)

mitoxantrone (novantrone) (1 trial)

nedaplatin (1 trial)

nimotuzumab (2 trials)

nivolumab (opdivo) (1 trial)

oprelvekin (Neumega) (1 trial)

osimertinib (tagrisso) (2 trials)

oxaliplatin (eloxatin) (4 trials)

paclitaxel (taxol) (16 trials)

pemetrexed (alimta) (3 trials)

pertuzumab (perjeta) (2 trials)

plb1001 (3 trials)

pm8002 (1 trial)

rc48-adc (1 trial)

savolitinib (1 trial)

shr-1316 (1 trial)

sildenafil (viagra) (1 trial)

sintilimab (4 trials)

sodium chloride (4 trials)

tamoxifen (nolvadex) (1 trial)

toremifene (fareston) (1 trial)

trastuzumab (herceptin) (5 trials)

tropisetron (1 trial)

vinorelbine (navelbine) (4 trials)

zirconium silicate (Lokelma) (1 trial)

Drugs in Phase 2 Trials (43)

ac0010ma (2 trials)

ak112 (1 trial)

ak119 (1 trial)

allogeneic stem cells (1 trial)

anlotinib (2 trials)

calcium (2 trials)

cetuximab (erbitux) (1 trial)

chidamide (2 trials)

cyclosporine (sandimmune) (2 trials)

eribulin (halaven) (1 trial)

esmolol (brevibloc) (1 trial)

etoricoxib (Gencox) (1 trial)

everolimus (zortress) (1 trial)

exemestane (aromasin) (1 trial)

gelofusin (1 trial)

gnc-038 (1 trial)

hlx10 (1 trial)

hs-10374 (1 trial)

human fecal microbiota (Reybota) (1 trial)

ifosfamide (ifex) (1 trial)

imatinib (gleevec) (1 trial)

IMMH-010 (1 trial)

kl590586 (1 trial)

lapatinib (tykerb) (3 trials)

lenalidomide (revlimid) (1 trial)

lorlatinib (lorbrena) (2 trials)

milrinone (primacor) (1 trial)

niraparib (zejula) (1 trial)

palbociclib (ibrance) (1 trial)

pegaspargase (oncaspar) (1 trial)

pembrolizumab (keytruda) (2 trials)

plb1004 (2 trials)

posaconazole (noxafil) (1 trial)

pyrotinib (1 trial)

raloxifene (evista) (1 trial)

regorafenib (stivarga) (1 trial)

rituximab (rituxan) (1 trial)

shr-1701 (1 trial)

Telitacicept (1 trial)

temozolomide (temodar) (1 trial)

tislelizumab (3 trials)

toripalimab (LOQTORZ) (1 trial)

triptorelin (Trelstar) (1 trial)

Drugs in Phase 1 Trials (14)

bat6021 (1 trial)

bpi-442096 (1 trial)

bronchial basal cells (1 trial)

cd19 car-t cells (1 trial)

doxorubicin (Doxil) (2 trials)

Getagozumab (1 trial)

glumetinib (1 trial)

IBI319 (1 trial)

js009 (1 trial)

lp-118 (1 trial)

qls1103 (1 trial)

sz011 (2 trials)

ticagrelor (brilinta) (1 trial)

volitinib (1 trial)

Drugs in Other Trials (21)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

azacitidine (vidaza) (1 trial)

bovine colostrum (1 trial)

colchicine (colbenemid) (1 trial)

ginseng (1 trial)

hemopoietic stem cell (1 trial)

heparin (liquaemin) (2 trials)

indocyanine green (ic-green) (2 trials)

lidocaine (xylocaine) (1 trial)

magnesium (1 trial)

methylene blue (proveblue) (2 trials)

methylprednisolone (medrol) (1 trial)

midazolam (versed) (1 trial)

oxygen (1 trial)

parecoxib (1 trial)

pinellia (1 trial)

remimazolam (Byfavo) (1 trial)

sacubitril (Entresto) (1 trial)

sodium citrate (1 trial)

sz003 (1 trial)

vinyl alcohol polymer (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Disease (Phase 1)

Amyloidosis (Phase 4)

Anemia (Phase 2)

Anemia, Aplastic (Phase 2)

Atrial Fibrillation (Phase 4)

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoid Tumor (Phase 2)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Cardiovascular Diseases (Phase 3)

Cerebral Small Vessel Diseases (Phase 4)

Cognitive Dysfunction (Phase 4)

Colorectal Neoplasms (Phase 3)

Communicable Diseases (Phase 4)

Compulsive Personality Disorder (Phase 4)

Cytomegalovirus Infections (Phase 2)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Dry Eye Syndromes (Phase 3)

Esophageal Neoplasms (Phase 3)

Esophageal Squamous Cell Carcinoma (Phase 2)

Essential Hypertension (Phase 3)

Familial Primary Pulmonary Hypertension (Phase 1)

Glaucoma (Phase 3)

Glomerulonephritis (Phase 4)

Glomerulonephritis, IGA (Phase 4)

Glomerulonephritis, Membranous (Phase 4)

Gout (Phase 3)

Graft vs Host Disease (Phase 3)

Head and Neck Neoplasms (Phase 3)

Hematologic Diseases (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Hypercalcemia (Phase 2)

Hyperglycemia (Phase 4)

Hyperhomocysteinemia (Phase 3)

Hyperparathyroidism (Phase 2)

Hypertension (Phase 4)

Hypertension, Pulmonary (Phase 3)

Immunoglobulin Light-chain Amyloidosis (Phase 4)

Infarction (Phase 2)

Infections (Phase 4)

Invasive Fungal Infections (Phase 4)

Keratoconjunctivitis Sicca (Phase 3)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Leukemia (Phase 4)

Leukemia, Lymphoid (Phase 4)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 4)

Leukemia, Myeloid (Phase 4)

Leukemia, Myeloid, Acute (Phase 4)

Liver Neoplasms (Phase 3)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 1)

Lung Neoplasms (Phase 4)

Lupus Nephritis (Phase 3)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Extranodal NK-T-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Musculoskeletal Pain (Phase 2)

Mycoses (Phase 4)

Myocardial Infarction (Phase 2)

Myocardial Reperfusion Injury (Phase 2)

Nasopharyngeal Carcinoma (Phase 3)

Nasopharyngeal Diseases (Phase 3)

Nasopharyngeal Neoplasms (Phase 3)

Neoplasm Metastasis (Phase 4)

Neoplasm, Residual (Phase 2)

Neoplasms (Phase 3)

Neoplasms, Second Primary (Phase 3)

Nephritis (Phase 3)

Nephrosis (Phase 4)

Nephrotic Syndrome (Phase 4)

Neuroendocrine Tumors (Phase 2)

Obsessive-Compulsive Disorder (Phase 4)

Ovarian Neoplasms (Phase 2)

Peritoneal Neoplasms (Phase 3)

Philadelphia Chromosome (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 4)

Prehypertension (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 1)

Renal Insufficiency, Chronic (Phase 4)

Reperfusion Injury (Phase 2)

Syndrome (Phase 3)

Thoracic Neoplasms (Phase 3)

Thrombocytopenia (Phase 3)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 197
  • # of Trial APIs: 195